News
Press Releases
TRexBio to Participate in Upcoming Investor Conferences in September
South San Francisco, Calif., September 3, 2025 – TRex Bio, Inc. (“TRexBio”), a clinical-stage biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced that members of its management team will participate in two...
TRexBio Doses First Participant in Phase 1 Trial of TRB-061, a Novel TNFR2 Agonist for Atopic Dermatitis and Other Inflammatory Diseases
Safety, pharmacokinetic, and pharmacodynamic data from healthy volunteers anticipated in 1H 2026 Designed to activate and expand tissue regulatory T cells (Tregs) without stimulating effector or innate immune cells, TRB-061 offers a potential new approach to immune...
TRexBio Expands Leadership Team with Appointments of Ariella Kelman, M.D., as Chief Medical Officer and Brandon Hants, MBA, as Chief Financial Officer
TRexBio Expands Leadership Team with Appointments of Ariella Kelman, M.D., as Chief Medical Officer and Brandon Hants, MBA, as Chief Financial Officer New appointments position TRexBio for clinical execution and company evolution as lead TNFR2 agonist program,...
TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development
Series B led by Delos Capital with participation from new and existing investors Proceeds support advancing wholly owned development candidate TRB-061, a novel TNFR2 agonist for the treatment of inflammatory diseases, through early clinical proof of...
TRexBio Announces Collaboration Partner Lilly Has Initiated a Phase 1 Study of TRB-051 for Autoimmune and Inflammatory Diseases
TRexBio has earned a double-digit million dollar milestone payment and is eligible to receive more than $1.1 billion on achievement of certain development, regulatory, and commercial milestones across partnered programs TRB-051 program is the first to enter the clinic...
TRexBio Announces a First Option Was Exercised by Partner under Immunology Discovery Collaboration
SOUTH SAN FRANCISCO, January 3, 2024 – TRex Bio, Inc. (“TRexBio”), a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced that Johnson & Johnson Innovative Medicine has exercised the first of its options...
